Clinical Trial to Evaluate Papilocare® Gel Efficacy Into Repairment of Cervical Lesions Caused by HPV

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 7, 2018

Primary Completion Date

November 30, 2022

Study Completion Date

January 20, 2023

Conditions
HPV InfectionLesion Cervix
Interventions
DEVICE

PAPILOCARE

"Papilocare®: Vaginal Gel based on Coriolus versicolor, medical device class IIa.~Route of administration: topical (vaginal). Papilocare® consists of the following ingredients: hyaluronic acid niosomes, β-glucans (magnolol, honokiol and carboxymethyl betaglucan) niosomes, BioEcolia® (Alpha-oligoglycan), Coriolus versicolor, Azadirachta indica (Neem) extract, Centella asiatica and Aloe vera."

DEVICE

PLACEBO

The placebo consists of a carrier gel with the absence of the active ingredients of Papilocare®.

Trial Locations (1)

38010

Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife

All Listed Sponsors
lead

Procare Health Iberia S.L.

INDUSTRY

NCT04210336 - Clinical Trial to Evaluate Papilocare® Gel Efficacy Into Repairment of Cervical Lesions Caused by HPV | Biotech Hunter | Biotech Hunter